Brenntag Specialties has completed the acquisition of Czech-based mcePharma, a strategic move designed to strengthen its position in the pharmaceutical and biopharmaceutical industries through expanded continuous monitoring platform (CMP) capabilities and enhanced presence in central Europe.
The acquisition positions Brenntag to develop a central hub for good manufacturing practice (GMP) value-added services across Europe, the Middle East and Africa (EMEA), addressing the increasing demand for customized solutions in the biopharma market. The transaction's signing and closing occurred simultaneously, though financial details were not disclosed.
Enhanced Manufacturing Capabilities
The mcePharma facilities bring advanced GMP infrastructure and over-the-counter product development capacity to Brenntag's portfolio. These existing capabilities will be integrated into Brenntag's broader life sciences service offering, expanding the company's operational reach across the EMEA region.
Brenntag has announced additional investment at the mcePharma site to scale GMP blending, down-packing and biobuffer production. The integration will also include expanded warehouse and office space, positioning the combined entity to meet growing demand while ensuring operational excellence.
"The integration of GMP blending and down-packing, along with added warehouse and office space, positions us to meet growing demand while ensuring operational excellence. It's a powerful enhancement to our portfolio that reinforces our commitment to quality, speed, and customer-centric solutions," said Joakim Rehnér, president Pharma EMEA at Brenntag.
Strategic Market Positioning
The acquisition represents a key milestone in Brenntag's strategic initiatives to expand its biopharma services. The existing GMP facilities, advanced sampling services, and expertise in both OTC product development and GMP powder pack-off will add to the growing portfolio of capabilities and value-added services Brenntag Pharma offers to principals and customers in the EMEA region.
Ivan Mikes, Member of the Administration Board of mcePharma, expressed enthusiasm about the partnership: "After growing our portfolio and expertise in development, production, and warehousing for distribution of specialty chemicals and services, we are excited to expand our reach and customer base significantly by joining Brenntag. Our team will get the chance to leverage their expertise and serve the entire EMEA region together with the Brenntag Pharma colleagues."
Gust Desmedt, global president pharma at Brenntag, commented: "This acquisition represents a key milestone in our strategic initiatives to further expand our biopharma services."
The acquisition is intended to improve operational efficiency and meet growing needs for high-quality, compliant formulation and distribution services in the expanding biopharma market across the EMEA region.
